Marine extracted polypeptide as well as preparation method and application thereof in lowering blood pressure
By extracting peptides P1, P2 and P3 from bonito, and preparing ACE inhibitors by biological enzymatic method, the gap and cost of marine peptides in lowering blood pressure is solved, safe and efficient blood pressure regulation is achieved, and marine resources are improved Utilization rate provides new methods for the treatment of hypertension.
Patent Information
- Application Number
- CN202411130420.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-16
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-08-16
AI Technical Summary
The prior art has not yet discovered the application of marine-derived bonito polypeptides in lowering blood pressure, and the cost of developing ACE inhibitors is high, and there are problems with safety and side effects.
By extracting polypeptides P1, P2 and P3 from bonito, polypeptides with ACE inhibitory function were prepared by biological enzymatic method, and using their application in lowering blood pressure, a green natural product is provided for the prevention and treatment of hypertension.
The obtained polypeptide significantly inhibits blood pressure increase, has excellent ACE inhibitory activity, is highly safe and has no toxic side effects, can effectively improve the utilization rate of marine resources, and provide new ways and new methods for the prevention and treatment of hypertension.
Smart Images

Figure CN118930609A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of polypeptides, and in particular relates to a polypeptide extracted from the ocean, a preparation method thereof, and an application thereof in lowering blood pressure. Background Art
[0002] Hypertension is a disease that is extremely harmful to human health and has a long incubation period. In the early stages of hypertension, there are generally no obvious symptoms until clinical signs of heart attack, cerebral vascular rupture, and death occur.
[0003] Angiotensin I converting enzyme (ACE) is a key enzyme in the renin-angiotensin system. Angiotensinogen is converted into angiotensin I under the action of renin, and angiotensin I is converted into angiotensin II under the action of ACE, which stimulates vasoconstriction and causes blood pressure to rise. Inhibiting the activity of ACE has a positive effect on lowering blood pressure, so the development of effective ACE inhibitors has attracted great attention. Although ACE inhibitory peptides derived from food are weaker than artificially synthesized ACE inhibitors, they have their unique advantages, will not cause the problem of excessive blood pressure reduction, are highly safe, have no side effects, and in addition to the blood pressure reduction function, often have the functions of promoting immunity and easy digestion and absorption. Therefore, the development and utilization of blood pressure-lowering functional factors in natural foods will become an important part of non-drug treatment of hypertension in the future.
[0004] Bonito (Latin name Katsuwonuspelamis) is a rich marine resource in my country. It is rich in protein, which is richer than that of ordinary fish. It also contains amino acids, calcium, iron and other elements required by the human body, which helps to maintain health and promote body functions. Therefore, the development and preparation of functional peptides using bonito has a good application prospect. In the article "Preparation, separation, structural characterization and efficacy mechanism of bonito uric acid-lowering peptides", Li Yujuan used papain to hydrolyze bonito protein to obtain oligopeptides less than 1000 Da with in vitro inhibition of xanthine oxidase (XO) activity. In "Study on the physiological activity of high F value oligopeptide liquid from bonito meat", Huang Cheng used pepsin and flavor enzymes for step-by-step hydrolysis to study the sobering and anti-fatigue effects of high F value oligopeptides. In the Chinese invention patent document CN116098984A, the application and experiment of bonito oligopeptides in the process of liver damage repair are disclosed. In the Chinese invention patent document CN117305398A, it is disclosed that bonito active peptides have the property of protecting pepsin activity. At present, the application of marine bonito peptides in lowering blood pressure has not been found.
[0005] Searching for antihypertensive active substances from marine organisms has become an important research direction for marine drugs and marine functional foods. my country is rich in marine fish resources. If a method for preparing angiotensin-converting enzyme inhibitory peptides using bonito can be provided, it will be able to greatly reduce production costs and provide high-quality fish protein peptides with ACE inhibitory function for the preparation of special foods and nutritional foods. SUMMARY OF THE INVENTION
[0007] In order to understand the problems existing in the prior art, the present invention provides a marine extracted polypeptide and a preparation method thereof and an application in lowering blood pressure. Specifically, polypeptides with blood pressure lowering function are obtained by extracting from bonito, and high-quality protein in bonito meat is scientifically utilized to develop polypeptide ACE inhibitors, which can provide important support for the development of bonito protein functional products and food-borne polypeptide antihypertensive drugs.
[0008] To this end, the present invention adopts the following technical solutions:
[0009] The present invention provides polypeptides P1, P2 and P3 having ACE inhibitory function.
[0010] Furthermore, the polypeptide amino acid sequence is P1 of FEFMIQKQ (SEQ ID NO.1), the amino acid sequence is P2 of DGPKLSADEN (SEQ ID NO.2), and the amino acid sequence is P3 of KLSADEN (SEQ ID NO.3).
[0011] Furthermore, the polypeptide is derived from bonito or is artificially synthesized.
[0012] The present invention provides a method for preparing the polypeptide, comprising the following steps:
[0013] (1) Raw material pretreatment: weigh 500 g of skinned bonito, wash it three times with 4°C clean water, grind it into minced meat, add pH 6.8 phosphate buffer at a material-liquid ratio of 1:5, soak it for two hours, and then wash it with clean water;
[0014] (2) Alkaline hydrolysis: adjust the pH to 7.8 with 1 M NaOH solution, add enzyme to start alkaline hydrolysis reaction, and obtain alkaline hydrolysis solution;
[0015] (3) Acid hydrolysis: adjust the pH of the alkaline hydrolysis solution to 2.0 with 0.5 M HCl solution, add enzyme to start the acid hydrolysis reaction, and obtain an acid hydrolysis solution;
[0016] (4) Inactivation of enzyme: After the enzymatic hydrolysis reaction is completed, the acid hydrolyzate is heated in a boiling water bath at 95°C for 15 min to inactivate the enzyme;
[0017] (5) solid-liquid separation: cooling to room temperature and centrifuging to obtain the bonito enzymatic hydrolysis supernatant;
[0018] (6) Desalting: The supernatant of the bonito enzymatic hydrolysis was desalted using a nanofiltration membrane with a molecular weight cutoff of 1000 Da, and the process was repeated three times to obtain a bonito polypeptide solution;
[0019] (7) adding the bonito polypeptide solution to Sephadex G-25 dextran gel for chromatographic separation, using deionized water as the eluent, collecting the separated peak components respectively, determining their inhibitory effects on ACE enzyme, and selecting the component with the highest inhibition rate for the next separation;
[0020] (8) Further purifying the component with the highest inhibition rate in step (7) by semi-preparative high performance liquid chromatography at a flow rate of 1 mL / min and a detection wavelength of 214 nm, eluting and collecting the elution peak; using UPLC-ESI-MS / MS to identify the amino acid sequence of the elution peak to obtain a polypeptide with an amino acid sequence of SEQ ID NO.1-3.
[0021] Furthermore, the enzyme added in step (2) is trypsin, the amount of enzyme added is 3000 U / g, the enzymatic hydrolysis temperature is 37° C., and the enzymatic hydrolysis time is 3 h.
[0022] Furthermore, the enzyme added in step (3) is pepsin, the enzyme addition amount is 4000U / g, the enzymolysis temperature is 37°C, and the enzymolysis time is 2h.
[0023] Furthermore, the elution procedure of step (8) is: 0-15 min, 5-15% B; 15-30 min, 15-20% B; 30-40 min, 20-30% B; 40-47 min, 30-45% B; 47-55 min, 45-50% B; wherein phase A is ultrapure water, and phase B is 0.1% TFA in acetonitrile solution;
[0024] The present invention also provides a polypeptide prepared by the preparation method.
[0025] The present invention also provides the use of the polypeptide in preparing blood pressure lowering drugs.
[0026] The present invention also provides the use of the polypeptide in preparing angiotensin converting enzyme inhibitors.
[0027] The present invention also provides food, health care products or medicines containing the polypeptide.
[0028] Compared with the prior art, the present invention has the following advantages and beneficial effects:
[0029] The present invention extracts and prepares ACE inhibitory peptides from bonito by adopting an environmentally friendly bioenzymatic hydrolysis method, and the obtained polypeptides FEFMIQKQ, DGPKLSADEN and KLSADEN have excellent ACE inhibitory activity and can significantly inhibit the increase of blood pressure. The preparation process of the present invention is scientific and reasonable, simple to operate, and has strong industrial feasibility; and the polypeptide sequence is clear and the number of amino acid residues is small, and it can be conveniently synthesized on a large scale, has no toxic side effects on vascular endothelial cells, and has good safety. The present invention makes high-value and accurate use of bonito protein resources, which can effectively improve the utilization rate of marine resources and industrial value, and also provides new ways and methods for preventing and treating hypertension. The bonito ACE inhibitory peptide of the present invention belongs to a green natural product, which can prevent, relieve and assist in the treatment of hypertension by eating, and is used to develop related health foods or drugs for the treatment of hypertension, and has broad market prospects in many fields such as health foods and medicines. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 The toxicity of peptides P1, P2 and P3 at different concentrations on HUVEC cells DETAILED DESCRIPTION
[0031] In order to explain in detail the possible application scenarios, technical principles, specific schemes that can be implemented, and the purposes and effects that can be achieved, the following is a detailed description of the specific embodiments listed in conjunction with the accompanying drawings. The embodiments described herein are only used to more clearly illustrate the technical solutions of the present application, and are therefore only used as examples, and cannot be used to limit the scope of protection of the present application.
[0032] Reference to "embodiment" herein means that the specific features, structures or characteristics described in conjunction with the embodiment may be included in at least one embodiment of the present application. The term "embodiment" appearing in various places in the specification does not necessarily refer to the same embodiment, nor does it particularly limit its independence or association with other embodiments. In principle, in the present application, as long as there is no technical contradiction or conflict, the various technical features mentioned in the embodiments can be combined in any way to form a corresponding implementable technical solution.
[0033] Unless otherwise defined, the technical terms used in this document have the same meanings as those generally understood by those skilled in the art to which this application belongs; the use of relevant terms in this document is only for describing specific embodiments and is not intended to limit this application.
[0034] Without further limitations, in this application, the words "include", "comprises", "has" or other similar expressions used in sentences are intended to cover non-exclusive inclusion. These expressions do not exclude the presence of additional elements in the process, method or product including the elements, so that the process, method or product including a series of elements may include not only those limited elements, but also other elements not explicitly listed, or also include elements inherent to such process, method or product.
[0035] Similar to the understanding in the Examination Guidelines, in this application, expressions such as "greater than", "less than", "exceed" and the like are understood to exclude the number itself; expressions such as "above", "below", "within" and the like are understood to include the number itself. In addition, in the description of the embodiments of this application, "multiple" means more than two (including two), and similar expressions related to "multiple" are also understood in this way, such as "multiple groups", "multiple times", etc., unless otherwise clearly and specifically limited.
[0036] Unless otherwise specified, the raw materials, reagents or devices used in the following examples can be obtained from conventional commercial sources or by existing known methods.
[0037] Example 1
[0038] A method for preparing a polypeptide having ACE inhibitory function, the specific steps are as follows:
[0039] (1) Raw material pretreatment: weigh 500 g of skinned bonito, wash it three times with 4°C clean water, grind it into minced meat, add pH 6.8 phosphate buffer at a material-liquid ratio of 1:5, soak it for two hours, and then wash it with clean water;
[0040] (2) Alkaline hydrolysis: adjust the pH to 7.8 with 1 M NaOH solution, add trypsin to start the alkaline hydrolysis reaction, add 3000 U / g enzyme, hydrolysis temperature 37 ° C, hydrolysis for 3 h, and obtain alkaline hydrolyzate;
[0041] (3) Acid hydrolysis: The alkaline hydrolyzate was adjusted to pH 2.0 with 0.5 M HCl solution, and pepsin was added to start the acid hydrolysis reaction. The enzyme addition amount was 4000 U / g, the enzymatic hydrolysis temperature was 37°C, and the enzymatic hydrolysis was carried out for 2 h to obtain the acid hydrolyzate;
[0042] (4) Inactivation of enzyme: After the enzymatic hydrolysis reaction is completed, the acid hydrolyzate is heated in a boiling water bath at 95°C for 15 min to inactivate the enzyme;
[0043] (5) solid-liquid separation: after cooling to room temperature, centrifuge at 10,000 rpm for 20 min to obtain the bonito enzymatic hydrolysis supernatant;
[0044] (6) Desalting: The supernatant of the bonito enzymatic hydrolysis was desalted using a nanofiltration membrane with a molecular weight cutoff of 1000 Da, and the process was repeated three times to obtain a bonito polypeptide solution;
[0045] (7) adding the bonito polypeptide solution to Sephadex G-25 dextran gel for chromatographic separation, using deionized water as the eluent, collecting the separated peak components respectively, determining their inhibitory effects on ACE enzyme, and selecting the component with the highest inhibition rate for the next separation;
[0046] (8) The component with the highest inhibition rate in step (7) was further purified by semi-preparative high performance liquid chromatography (the semi-preparative liquid phase model was Agilent 1260 Infinity semi-prep arative HPLC, equipped with an automatic collector, the chromatographic column was AdvanceBio Peptide Map C18 chromatographic column, and the column temperature was 40°C), the flow rate was 1 mL / min, the detection wavelength was 214 nm, the elution program was as shown in Table 1, and the elution peak was collected; the amino acid sequence of the elution peak was identified by UPLC-ESI-MS / MS to obtain ACE inhibitory peptide P1, whose amino acid sequence was FEFMIQKQ (SEQ ID NO.1); ACE inhibitory peptide P2, whose amino acid sequence was DGPKLSADEN (SEQ ID NO.2); ACE inhibitory peptide P3, whose amino acid sequence was KLSADEN (SEQ ID NO.3).
[0047] Table 1 HPLC elution program
[0048]
[0049] Example 2
[0050] Shanghai Jier Biochemical Co., Ltd. was commissioned to synthesize peptides P1: FEFMIQKQ (SEQ ID NO.1), P2: DGPKLSADEN (SEQ ID NO.2) and P3: KLSADEN (SEQ ID NO.3), with a purity of more than 98%.
[0051] Determination of ACE inhibition rate of SEQ ID NO.1-3 polypeptides:
[0052] (1) Solution preparation
[0053] 0.1mol / L borate buffer (pH 8.3, containing 0.3mol / L sodium chloride): weigh 1.730g of boric acid, heat to dissolve, and dilute to 100mL for use; weigh 1.907g of borax (Na2B4O7·10H2O), heat to dissolve, and dilute to 100mL for use; measure 32.5mL of the above boric acid solution and 17.5mL of the above borax solution, mix well, adjust the pH to 8.3, and then add 1.753g of sodium chloride and dilute to 100mL.
[0054] 0.125U / mL ACE enzyme solution: Take 0.5U ACE enzyme and dilute to 4mL with deionized water.
[0055] 0.25mmol / L N-[3-(2-furyl)acryloyl]-L-phenylalanamide-glycine-glycine solution (FAPGG): weigh 5.0mg FAPGG powder, dissolve it with the above 0.1mol / L borate buffer (pH 8.3, containing 0.3mol / L sodium chloride) and make up to 50mL.
[0056] Preparation of peptide sample solutions: Synthetic peptides P1, P2 and P3 were prepared into solutions with mass concentrations of 0.05 mg / mL and 0.1 mg / mL, respectively.
[0057] (2) Experimental methods
[0058] Pipette 550 μL of the polypeptide sample solution, add 275 μL of the above FAPGG solution, mix, then add 275 μL of the above ACE enzyme solution, measure the absorbance at 340 nm immediately after mixing, then incubate at 37°C for 30 min, and measure the absorbance at 340 nm again after the reaction is completed; use deionized water instead of the polypeptide sample solution as a control.
[0059] (3) Calculation formula
[0060] The ACE inhibitory activity was calculated as follows: In the formula: A1 represents the initial absorbance value of the sample group; A2 represents the absorbance value of the sample group after 30 minutes of reaction; A3 represents the initial absorbance value of the control group; A4 represents the absorbance value of the control group after 30 minutes of reaction.
[0061] Table 2 ACE inhibition rate of peptides
[0062]
[0063] The results in Table 2 show that the polypeptides FEFMIQKQ, DGPKLSADEN and KLSADEN all have excellent ACE inhibitory activity, among which the polypeptide with the amino acid sequence of KLSADEN exhibits the best ACE inhibitory effect, and the ACE inhibition rate reaches more than 90% at 0.1 mg / mL. That is, the polypeptide prepared by the present invention has a significant ACE inhibitory effect and has a good application prospect.
[0064] Example 3
[0065] Cytotoxicity evaluation test, to determine its toxicity to human umbilical vein endothelial cells (HUVECs):
[0066] HUVEC cells with good growth status were selected and DMEM medium was added to make single cell suspension. The cells were counted with a hemocytometer and the number of cells was 1×10 5 The cells were inoculated at a density of 100 μL / mL in a 96-well plate, with 100 μL of cell suspension in each well, and cultured in an incubator at 37°C and 5% CO2 saturated humidity. After 24 hours of cell culture, the complete culture medium was aspirated. The peptide solution diluted with high-glucose DMEM medium at concentrations of 0.05 mg / mL and 0.1 mg / mL was added to the experimental group (3 replicates were set for each concentration), the control group was cells cultured in DMEM medium, and the blank group was DMEM medium without cells, and continued to be cultured in an incubator at 37°C and 5% CO2 saturated humidity for 24 hours. 10 μL of CCK-8 reagent was added to each group, incubated in a cell culture incubator for 2 hours, and the absorbance value (OD value) of each well was measured at a wavelength of 450 nm using an enzyme-linked immunosorbent assay. The cell survival rate was calculated according to the mean absorbance of each group according to the following formula:
[0067]
[0068] The experimental results are as follows Figure 1 As shown, the cell viability of each experimental group was above 100%, indicating that the ACE inhibitory peptides prepared by the present invention had no cytotoxicity and good safety.
[0069] Example 4
[0070] In vivo blood pressure lowering test in rats:
[0071] (1) Experimental animals
[0072] SPF Wistar rats, half male and half female, were purchased from Jinan Pengyue Experimental Animal Breeding Co., Ltd., license number: SCXK Lu 20140007, with a body weight of 200 ± 20 g and a normal diet.
[0073] (2) Modeling
[0074] 45mg / kg sodium pentobarbital solution was intraperitoneally injected into SD rats. The skin on the left side of the rat's abdomen was disinfected with 75% alcohol. An incision was made along the left hypochondrium 1.5-2.0cm below the costal margin and about 1.0cm from the spine. The left renal artery was carefully separated with a glass rod and ligated with sutures. After the operation, the muscles and skin were sutured layer by layer. After suturing, 2×10 penicillin sodium was injected intraperitoneally. 5 U was used to prevent postoperative wound infection. Ten Wistar rats in the blank group underwent sham surgery without ligating the left renal artery. The systolic blood pressure of the tail artery of the operated rats was measured 4 weeks after surgery. Rats with a blood pressure higher than 160 mmHg were considered to have successfully established a model of renal hypertension.
[0075] (3) Group experiment
[0076] The rats with renal hypertension model successfully established above were divided into model group, drug administration group (polypeptide P1, P2 and P3) and positive group, and 10 normal Wistar rats were taken as normal group, with half male and half female in each group. The drug administration group was administered with polypeptide P1, P2 and P3 at a dose of 40 mg / kg body weight. The positive group was administered with captopril (Zhengzhou Taifeng Pharmaceutical Co., Ltd., national medicine standard H41021750) at the same dose. All drugs were administered for 6 consecutive weeks, once a day, and the blank group and the model group were given an equal volume of normal saline by gavage every day.
[0077] (4) Observation indicators
[0078] 2 hours after the last administration, the blood pressure of rats in each group was measured, and the rats were killed by cervical dislocation. Blood was collected, serum was separated, and ELISA kits (Feiyue Biotechnology) were used to detect the levels of angiotensin I (AngI), angiotensin II (AngII), and aldosterone (ALD) in rat plasma. The product numbers were FY-ERM14501, FY-ERM14502, and FY-EU6455, respectively.
[0079] (5) Statistical analysis
[0080] All test data were expressed as mean and standard deviation, and SPSS13.0 software was used to process the data.
[0081] (6) Results
[0082] Table 3 Blood pressure measurement results
[0083]
[0084]
[0085] Note: Compared with the normal group, # P<0.05; compared with the model group, *P<0.05.
[0086] The results show that, compared with the normal group, the blood pressure of the rats in the model group, positive group and drug-treated group was significantly higher than that of the normal group at 4 weeks after surgery, and the average systolic blood pressure exceeded 160 mmHg, indicating that the model was successfully established.
[0087] The rats in the drug-treated group and the positive group began intervention treatment at the 4th week after surgery. After the 6th week of drug administration, the average systolic blood pressure of the rats decreased significantly compared with the 4th week after surgery, indicating that intervention treatment with captopril or polypeptides P1, P2 and P3 in the renal hypertension model rats can achieve the effect of significantly lowering their blood pressure, indicating that the polypeptides P1, P2 and P3 prepared by the present invention have a blood pressure-lowering effect comparable to that of captopril.
[0088] Table 4 Biochemical index measurement results
[0089] Group AngI (ng / L) AngII (ng / L) ALD(μg / L) Normal group 9.65±1.35 368.58±23.15 0.18±0.03 Model Group <![CDATA[16.28±3.14 # ]]> <![CDATA[1253.16±121.60 # ]]> <![CDATA[0.34±0.06 # ]]> Positive group 12.25±2.18* 378.43±52.15* 0.20±0.03* Peptide P1 12.68±2.06* 384.65±64.12* 0.21±0.04* Peptide P2 11.54±1.88* 391.24±45.85* 0.18±0.02* Peptide P3 14.24±2.35 370.15±52.33* 0.20±0.04*
[0090] Note: Compared with the normal group, # P<0.05; compared with the model group, *P<0.05.
[0091] As shown in Table 4, compared with the normal group, the levels of AngI, AngII and ALD in the serum of the rats in the model group were significantly higher than those in the normal group, further indicating that the model was successfully established.
[0092] After the renal hypertension model rats were intervened with captopril, the contents of AngI, AngII and ALD were significantly reduced compared with the model group. In the drug administration group, after the intervention treatment of the renal hypertension model rats by polypeptides P1, P2 and P3, the contents of AngI, AngII and ALD were also significantly reduced compared with the model group. This shows that the polypeptides P1, P2 and P3 prepared by the present invention can significantly reduce the contents of AngI, AngII and ALD in the serum of the renal hypertension model rats.
[0093] The bonito polypeptides P1, P2 and P3 prepared by the invention can improve the imbalance of renin-angiotensin-aldosterone system (RAAS), lower blood pressure, and have potential application prospects in the fields of improving hypertension.
[0094] The above contents are further detailed descriptions of the present invention in combination with specific preferred embodiments, and it cannot be determined that the specific implementation of the present invention is limited to these descriptions. For ordinary technicians in the technical field to which the present invention belongs, several simple deductions or substitutions can be made without departing from the concept of the present invention, which should be regarded as falling within the protection scope of the present invention.
Claims
1. A polypeptide having ACE inhibitory function, characterized in that: The polypeptide is selected from: P1 with an amino acid sequence of SEQ ID NO.1, P2 with an amino acid sequence of SEQ ID NO.2, and P3 with an amino acid sequence of SEQ ID NO.
3.
2. The polypeptide according to claim 1, characterized in that The polypeptide is derived from bonito or is artificially synthesized.
3. A method for preparing the polypeptide according to claim 1, characterized in that: The following steps are involved: (1) Raw material pretreatment: Weigh 500 g of skinned bonito, wash it three times with 4°C clean water, grind it into minced meat, add pH 6.8 phosphate buffer at a material-liquid ratio of 1:5, soak it for two hours, and then wash it with clean water; (2) Alkaline hydrolysis: adjust the pH to 7.8, add enzyme to start the alkaline hydrolysis reaction, and obtain alkaline hydrolysis solution; (3) Acid hydrolysis: adjust the pH of the alkaline hydrolysis solution to 2.0, add enzyme to start the acid hydrolysis reaction, and obtain the acid hydrolysis solution; (4) Inactivation of enzyme: After the enzymatic hydrolysis reaction is completed, the acid hydrolyzate is heated in a boiling water bath at 95°C for 15 min to inactivate the enzyme; (5) Solid-liquid separation: Cool to room temperature and centrifuge to obtain the bonito enzymatic hydrolysis supernatant; (6) Desalting: The supernatant of the bonito enzymatic hydrolysis was desalted using a nanofiltration membrane with a molecular weight cutoff of 1000 Da, and the process was repeated three times to obtain a bonito polypeptide solution; (7) Adding the bonito polypeptide solution to Sephadex G-25 dextran gel for chromatographic separation, using deionized water as the eluent, collecting the separated peak components respectively, determining their inhibitory effects on ACE enzyme, and selecting the component with the highest inhibition rate for the next separation; (8) The component with the highest inhibition rate in step (7) was further purified by semi-preparative high performance liquid chromatography at a flow rate of 1 mL / min and a detection wavelength of 214 nm, and the eluted peak was collected; the amino acid sequence of the eluted peak was identified by UPLC-ESI-MS / MS to obtain a polypeptide with an amino acid sequence of SEQ ID NO.1-3.
4. The preparation method according to claim 3, characterized in that: The enzyme added in step (2) is trypsin, the amount of enzyme added is 3000 U / g, the enzymatic hydrolysis temperature is 37° C., and the enzymatic hydrolysis is carried out for 3 hours.
5. The preparation method according to claim 3, characterized in that: The enzyme added in step (3) is pepsin, the amount of enzyme added is 4000 U / g, the enzymolysis temperature is 37° C., and the enzymolysis is carried out for 2 h.
6. The preparation method according to claim 3, characterized in that: The elution procedure of step (8) is: 0-15 min, 5-15% B; 15-30 min, 15-20% B; 30-40 min, 20-30% B; 40-47 min, 30-45% B; 47-55 min, 45-50% B; wherein phase A is ultrapure water and phase B is 0.1% TFA in acetonitrile solution.
7. A polypeptide obtained by the preparation method according to any one of claims 3 to 6.
8. Use of the polypeptide according to any one of claims 1 or 7 in the preparation of a blood pressure lowering drug.
9. Use of the polypeptide according to any one of claims 1 or 7 in the preparation of angiotensin converting enzyme inhibitors.
10. Food, health product or medicine containing the polypeptide according to any one of claims 1 or 7.
Citation Information
Patent Citations
Miscellaneous fish enzymolysis polypeptide and uses thereof
CN101225105A
Fish protein peptide with ACE inhibitory function and preparation method thereof
CN106434809A
Antihypertensive active peptide and application thereof
CN115677834A
Mackerel ACE (angiotensin converting enzyme) inhibitory peptide as well as preparation method and application thereof
CN116003513A
Novel angiotensin I converting enzyme (ACE) inhibitory peptide
CN116507734A
